Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Efficacy and Safety of Icaritin Versus Cinobufotalin in First-line Treatment of Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Double-blind, Double-dummy Phase III Clinical Trial

NCT03236636 is registered in ClinicalTrials.gov with Beijing Shenogen Biomedical Co., Ltd as lead sponsor.

NCT NCT03236636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03236636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Efficacy and Safety of Icaritin Versus Cinobufotalin in First-line Treatment of Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Double-blind, Double-dummy Phase III Clinical Trial
Lead sponsor
Beijing Shenogen Biomedical Co., Ltd
Phase
Phase 3
Overall status
Unknown status
Start date
September 8, 2017
Completion date
December 30, 2022
Enrollment
312 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hbv-related hepatocellular carcinoma (hcc)